Phenylketonuria (PKU) is a treatable inherited metabolic condition in which phenylalanine can accumulate to harmful levels. Phenylalanine is an amino acid obtained from food. Early detection and sustained care protect development; an apparently well baby still needs prompt follow-up of an abnormal newborn screen. [1][2]
In this guide: An abnormal newborn screen: what happens next? · PKU, PAH deficiency and high phenylalanine · Why does care continue beyond childhood? · What does the inheritance pattern mean? · Why discuss pregnancy before conception? · How can I judge a PKU treatment study? · Continue with evidence and care tools
An abnormal newborn screen: what happens next?
A screening result identifies a need for investigation; it does not, by itself, establish PKU. Follow-up can include blood, urine and genetic testing. Complete the recommended assessment promptly and follow the newborn-screening team’s instructions rather than waiting for symptoms. [2]
- Confirm contact: record the name and number of the team arranging follow-up.
- Clarify timing: ask when and where the next sample should be taken.
- Keep the original result: retain the value, units, date and laboratory interpretation.
- Ask about feeding: obtain a specific plan from the metabolic team; do not improvise a restrictive infant diet.
- Close the loop: agree who will communicate the confirmatory result and what happens if no call arrives.
For example, a message saying “phenylalanine is high” is incomplete. A useful handover adds the actual result, whether it came from screening or diagnostic testing, what the laboratory recommends, and the follow-up appointment. This organizational step helps prevent a screening alert from being mistaken for a finished diagnosis.
PKU, PAH deficiency and high phenylalanine
PAH deficiency is a spectrum; PKU is commonly used for its more severe forms. Other causes of elevated phenylalanine must also be considered, including disorders involving the cofactor tetrahydrobiopterin (BH4). Biochemical and molecular evidence are complementary. Necessary treatment should not be delayed while waiting for the genetic result. [3]
Ask the clinician which diagnosis is established and which alternatives have been assessed. A biochemical description such as hyperphenylalaninemia means high phenylalanine; it does not automatically identify the molecular cause. The PAH gene guide explains how enzyme function and genetic testing fit together.
Why does care continue beyond childhood?
Management can involve an individualized phenylalanine-controlled diet, medical nutritional products, monitoring and appropriate medicines. Requirements vary between people. The ACMG guideline emphasizes sustained metabolic control and lifelong management when treatment is indicated, using dietary, pharmaceutical and educational approaches. [1][4]
A practical care record should make the plan usable at home, school, university and work. Keep the current food or formula prescription separate from general online food lists. Record whom to contact if supplies are unavailable, eating becomes difficult, or the planned blood sample cannot be obtained. Ask for help with access and affordability rather than silently abandoning the plan.
- What phenylalanine range has my team set, and which sample and units are used?
- How often should samples be collected, and who reviews trends?
- How will nutritional adequacy and growth be assessed?
- Which treatment options are relevant to my age and circumstances?
- What support is available for attention, mood, learning or treatment burden?
- How will care transfer from pediatric to adult services?
What does the inheritance pattern mean?
PAH deficiency is autosomal recessive. When both biological parents carry a causative PAH variant, each pregnancy has a 25% probability of an affected child. A family may have no previously recognized diagnosis. These probabilities apply to that defined parental situation, not to every couple with a relative who has PKU. [2]
Start family discussions with the confirmed laboratory report. Distinguish an affected relative, a documented carrier and an untested person. Read the cascade testing guide for a method of organizing known familial findings without assigning results to relatives who have not been tested.
Why discuss pregnancy before conception?
High maternal phenylalanine can harm fetal development even when the baby does not inherit PKU. Preconception planning and metabolic control during pregnancy therefore address a different question from the baby’s inheritance probability. Contact the metabolic team early to plan individualized care. [2][4]
How can I judge a PKU treatment study?
Separate a change in blood phenylalanine from changes in cognition, nutrition, daily functioning or treatment burden. Record the baseline treatment, age range, follow-up and adverse events. A short study of one laboratory endpoint cannot answer every question about long-term experience.
Try a journal-club worksheet with five headings: participants, intervention, comparator, measured outcome and unanswered question. Note whether participants continued other treatments. Use our endpoint guide to identify what the trial actually demonstrates.
Continue with evidence and care tools
Read the PAH gene guide and what genetic tests can miss. Use the variant research assistant, care finder and literature tools for non-identifying research questions and professional directories. They do not replace newborn-screen follow-up or a metabolic diet prescription.
Educational information, not an individual diagnosis or treatment plan. The current specialist-review status appears above. Illustrations are original educational examples, not patient records.